Gemcitabine treatment of tumor-bearing mice reduced the number of splenic and tumor Gr1+/CD11b+ MDSC without affecting the numbers of CD4+ or CD8+ T cells or NK cells [75]. This evidence concerns the gene CD8A and neoplasm.